NCT04087018: Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: TMB-H
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated unstable brain or leptomeningeal metastases- see trial for details; Patients who have received prior treatment with temozolomide (TMZ) or an anti-PD-L1, anti-PD-1, anti-CTLA-4, or other immune checkpoint inhibitor

Comments are closed.

Up ↑